Alzheimer’s Therapy Market By Drug Class (Cholinesterase Inhibitors, N-Methyl D-Aspartate Antagonist, Combination Drugs, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Alzheimer’s Therapy market size was valued at USD 4,211.8 million in 2022 and is expected to grow at a 16.3% CAGR from 2023 to 2029. Alzheimer’s disease is a neurological disorder that causes the brain to shrink and brain cells to die. Alzheimer’s disease is the most common cause of dementia that leads to continuous decline in thought process, social and behavioural skills that affect the ability of a person to function independently. The early symptoms of Alzheimer’s disease include forgetting recent events or conversations. An Alzheimer diseased patient portal will have a severe memory loss and lose the ability to carry out everyday tasks as the disease progresses. The rise in prevalence of Alzheimer’s disease in emerging countries and developed countries is expected to drive the market growth in the forecasted period. In addition, the increase in occurrence of Alzheimer’s disease across the globe by the diagnosis of patients has boosted the Alzheimer’s disease therapy. According to Alzheimer’s Association, approximately 6 million people are living with Alzheimer’s in USA and it can be expected to reach 13 Million by 2050. Moreover, availability of various drug class for Alzheimer’s disease is expected to boost to growth of Alzheimer’s disease market. The increase in number of Alzheimer disease cases thus increases the demand for Alzheimer’s therapy. Advancement in the treatment, and drug discovery techniques drives the demand for Alzheimer’s therapy across the globe. Rising investment in research and development of innovative drugs by the key pharmaceutical companies is expected to fuel the growth Alzheimer’s disease market. In addition, the presence of pipeline drugs in the clinical trial phase is expected to boost the growth of Alzheimer’s market in a significant rate in the forecasted period. Geographically, North America region held the major market share in 2022 and is expected to dominate the global Alzheimer’s therapy market in the forecasted years.

Alzheimer’s Therapy Market Key Developments:
In October 2022, Cyclo Therapeutics Inc. commenced their phase II study of their pipeline drug ‘Trappsol Cyclo’.
In January 2023, the U.S. Food and Drug Administration approved Eisai, Inc.’s Leqembi via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.

Alzheimer’s Therapy Market Summary

Study Period

2023– 2029

Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Alzheimer’s Therapy Market Dynamics

Alzheimer’s therapy market is expected to grow due to the increasing prevalence of Alzheimer’s disease across the globe. Advancement of technology and innovation of new drugs is expected to drive the growth of Alzheimer’s disease market. Availability of various drug class for Alzheimer’s disease, presence of several pipeline drugs in the clinical trial phase is expected to fuel the growth of Alzheimer’s therapy market. The rising investment in the research and development of new drugs by the key pharmaceutical companies is expected to propel the market growth at a significant in the forecasted period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Alzheimer’s Therapy Market Segmentation

By Drug Class
  • Cholinesterase Inhibitors
  • N-Methyl D-Aspartate Antagonist
  • Combination Drugs
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA


Frequently Asked Questions

Alzheimer’s Therapy market was valued at USD 4,211.8 million in 2022 and is expected to grow at a 16.3% CAGR from 2023 to 2029

The discontinuation of Alzheimer’s therapy due to the lack of efficacy and lack of improvement in cognitive function is expected to restrain the growth of Alzheimer’s therapy market.

The leading players in the global Alzheimer’s Therapy market are Eisai Co., Ltd., Novartis AG., AbbVie Inc., Adamas Pharmaceuticals, Inc., H. Lundbeck A/S., Biogen, AC Immune., Cyclo Therapeutics Inc., F. Hoffmann La Roche Ltd., Daiichi Sankyo Company, Limited., Johnson & Johnson Services, Inc., TauRx Pharmaceuticals Ltd.

  • Eisai Co., Ltd.
  • Novartis AG.
  • AbbVie Inc.
  • Adamas Pharmaceuticals, Inc.
  • H. Lundbeck A/S.
  • Biogen.
  • AC Immune.
  • Cyclo Therapeutics Inc.
  • F. Hoffmann La Roche Ltd.
  • Daiichi Sankyo Company, Limited.
  • Johnson & Johnson Services, Inc.
  • TauRx Pharmaceuticals Ltd.